Clinical Trial Evaluating DC/AML Fusion Cell Vaccination Alone and in Conjunction with PD-1 Blockade in AML Patients Who Achieve a Chemotherapy-Induced Remission

Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), David Avigan(Beth Israel Deaconess Medical Center), Donna Neuberg(Otsuka (Japan)), D. Tzachanis(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center), Poorvi Somaiya(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), D. Steesma(Dana-Farber Cancer Institute), Robin Joyce(Beth Israel Deaconess Medical Center), Lowell T. Nicholson(Dana-Farber Cancer Institute), Emily Yuan(Beth Israel Deaconess Medical Center), Jessica Bonhoff(Beth Israel Deaconess Medical Center), Natalie Drummy(Beth Israel Deaconess Medical Center), Lynne Uhl(Hadassah Medical Center), Carol Delaney(Beth Israel Deaconess Medical Center), Ilene Galinsky(Dana-Farber Cancer Institute), Katarina Luptakova(Tesaro (United States)), Jacob M. Rowe(Technion – Israel Institute of Technology), Richard M. Stone(Dana-Farber Cancer Institute), Baldev Vasir(Beth Israel Deaconess Medical Center), Irit Avivi(Tel Aviv Sourasky Medical Center), Daniel J. DeAngelo(Dana-Farber Cancer Institute), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), D Kufe, Terry Katz(Rambam Health Care Campus), James D. Levine(Beth Israel Deaconess Medical Center), Viki Held(Beth Israel Deaconess Medical Center)

Transplantation and Cellular Therapy

January 10, 2012

Cited by 2

|New England Journal of Medicine|2017|6k

|Nature Immunology|2001|3k

|Nature|2017|3k

|New England Journal of Medicine|2017|2.2k

|New England Journal of Medicine|2012|1.9k

Related Papers